Procenta® Placental Derived Allograft
Wound Healing / Tissue Repair
CommercialActive
Key Facts
About Lucina Biosciences
Lucina Biosciences is a private, pre-revenue biotech firm pioneering the development of placental tissue-derived allografts. The company leverages state-of-the-art processing facilities to create biologic products intended to enhance clinical outcomes in wound care and tissue repair. Led by a small, experienced team, Lucina's strategy is built on a foundation of stringent regulatory compliance and scientific innovation within the growing regenerative medicine market. Its primary commercial asset appears to be the Procenta® placental derived allograft.
View full company profileTherapeutic Areas
Other Wound Healing / Tissue Repair Drugs
| Drug | Company | Phase |
|---|---|---|
| Axolotl Graft Portfolio Clinical Validation | Axolotl Biologix | Post-Market Study |